{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:43:30Z","timestamp":1786358610636,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1097\/hjh.0b013e328014954d","type":"journal-article","created":{"date-parts":[[2007,3,6]],"date-time":"2007-03-06T04:03:39Z","timestamp":1173153819000},"page":"891-894","source":"Crossref","is-referenced-by-count":105,"title":["Low-dose spironolactone in the management of resistant hypertension: a surveillance study"],"prefix":"10.1097","volume":"25","author":[{"given":"Deirdre A","family":"Lane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D Gareth","family":"Beevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-23-20210208","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/0003-4819-126-10-199705150-00002","article-title":"Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators","volume":"126","author":"Gueyffier","year":"1997","journal-title":"Ann Intern Med"},{"key":"R2-23-20210208","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"R3-23-20210208","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.jhh.1001683","article-title":"Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society 2004 \u2013 BHS IV","volume":"18","author":"Williams","year":"2004","journal-title":"J Hum Hypertens"},{"key":"R4-23-20210208","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/ajkd.2000.16225","article-title":"Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group","volume":"36","author":"Bakris","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"R5-23-20210208","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/sj.jhh.1001823","article-title":"How many antihypertensives do patients need to achieve a target blood pressure?","volume":"19","author":"Marshall","year":"2005","journal-title":"J Hum Hypertens"},{"key":"R6-23-20210208","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"key":"R7-23-20210208","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","article-title":"The role of spironolactone in the treatment of patients with refractory hypertension","volume":"15","author":"Ouzan","year":"2002","journal-title":"Am J Hypertens"},{"key":"R8-23-20210208","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomised Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R9-23-20210208","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/clpt.1980.75","article-title":"Amiloride, spironolactone and potassium chloride in thiazide treated hypertensive patients","volume":"27","author":"Ramsay","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"R10-23-20210208","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/dtb.26.22.88","article-title":"Spironolactone: no longer for hypertension.","volume":"26","year":"1988","journal-title":"Drug Ther Bull"},{"key":"R11-23-20210208","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00004872-200102000-00022","article-title":"Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions","volume":"19","author":"Burnier","year":"2001","journal-title":"J Hypertens"},{"key":"R12-23-20210208","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/bmj.287.6385.88","article-title":"Factors predictive of attendance at clinic and blood pressure control in hypertensive patients","volume":"287","author":"Degoulet","year":"1983","journal-title":"BMJ"},{"key":"R13-23-20210208","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0895-7061(01)02193-8","article-title":"Is resistant hypertension really resistant?","volume":"14","author":"Brown","year":"2001","journal-title":"Am J Hypertens"},{"key":"R14-23-20210208","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"R15-23-20210208","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"issue":"Suppl. 2","key":"R16-23-20210208","first-page":"326","article-title":"Frusemide and spironolactone in resistant hypertension: a controlled trial","volume":"1","author":"Freestone","year":"1988","journal-title":"J Hypertens"},{"key":"R17-23-20210208","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/bmj.300.6730.975","article-title":"Relation between dose of bendrofluazide, antihypertenive effect, and adverse biochemical effects","volume":"300","author":"Carlsen","year":"1990","journal-title":"BMJ"},{"key":"R18-23-20210208","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/00129784-200505030-00004","article-title":"Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect","volume":"5","author":"Meredith","year":"2005","journal-title":"Am J Cardiovasc Drugs"},{"key":"R19-23-20210208","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/bmj.327.7407.147","article-title":"Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases","volume":"327","author":"Wrenger","year":"2003","journal-title":"BMJ"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004872-200704000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T17:40:22Z","timestamp":1683740422000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004872-200704000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e328014954d","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1085806.538722","asserted-by":"object"}]},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}